CENTOGENE today announced the launch of CentoMetabolic®, a first-line test for the widest range of rare genetic metabolic diseases. By combining genetic and biochemical testing, CentoMetabolic® allows for immediate confirmation, and for many diagnoses a better understanding of the course of the disease, enhanced treatment monitoring, and tailored treatment guidance.
The differential diagnosis of a suspected genetic disorder often requires the analysis of multiple genes, for example conditions that show similar or overlapping phenotypes. CentoMetabolic® includes as many as 166 genes. The panel was developed specifically for patients suspected to have a metabolic disorder or presenting complex, overlapping symptoms, a metabolic crisis or neurological conditions of unknown etiology. CentoMetabolic® provides short turn-around-times targeting critically ill patients in NICU/PICU, and includes enzyme-activity testing where applicable, and a proprietary selection of biomarkers that is continually updated.
“The introduction of CentoMetabolic® is a natural extension of our global knowledge and expertise, as it provides physicians and their patients with the confidence that they are receiving an accurate diagnosis of their suspected genetic metabolic condition,” said Dr. Arndt Rolfs, CEO and founder of CENTOGENE. “Our rapid testing coupled with our unparalleled experience in metabolic disease genetics may put patients on the path to more immediate medical management, in particular in NICU or PICU, which is at the heart of CENTOGENE —reducing patients’ diagnostic odyssey and creating new hope for our patients and their families.”